CA Patent

CA2277949A1 — Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 1998-08-27 · 28y expired

What this patent protects

The invention relates to new disubstituted bicyclic heterocycles of the general formula (I): R a-A-Het-B-Ar-E, in which A, B, Ar, Het and R a are defined as in claim 1. The invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have…

USPTO Abstract

The invention relates to new disubstituted bicyclic heterocycles of the general formula (I): R a-A-Het-B-Ar-E, in which A, B, Ar, Het and R a are defined as in claim 1. The invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have valuable properties. The compounds of the above general formula (I), in which E is a cyano group, thus represent valuable intermediate products for the production of the other compounds of the general formula (I). Furthermore, the compounds of the above general formula (I), in which E stands for a R b NH-C(=NH)-group, have valuable pharmacological properties, in particular in inhibiting thrombin and prolonging thrombin time.

Drugs covered by this patent

Patent Metadata

Patent number
CA2277949A1
Jurisdiction
CA
Classification
Expires
1998-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.